|
1
|
Su Y, Zhao B, Guo F, Bin Z, Yang Y, Liu S,
Han Y, Niu J, Ke X, Wang N, et al: Interaction of benzo[a]pyrene
with other risk factors in hepatocellular carcinoma: A case-control
study in Xiamen, China. Ann Epidemiol. 24:98–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen M, Therneau T, Orsini LS and Qiao YL:
Design and rationale of the hcc bridge study in China: A
longitudinal, multicenter cohort trial in hepatocellular carcinoma.
BMC Gastroenterol. 11:532011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C,
Lv Y, Zhou Z and Liu Z: Hepatocellular carcinoma in a large medical
center of China over a 10-year period: Evolving therapeutic option
and improving survival. Oncotarget. 6:4440–4450. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu L, Miao R, Yang H, Lu X, Zhao Y, Mao
Y, Zhong S, Huang J, Sang X and Zhao H: Prognostic factors after
liver resection for hepatocellular carcinoma: A single-center
experience from China. Am J Surg. 203:741–750. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee SC, Tan HT and Chung MC: Prognostic
biomarkers for prediction of recurrence of hepatocellular
carcinoma: Current status and future prospects. World J
Gastroenterol. 20:3112–3124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Francis NJ and Kingston RE: Mechanisms of
transcriptional memory. Nat Rev Mol Cell Biol. 2:409–421. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koppens M and van Lohuizen M:
Context-dependent actions of polycomb repressors in cancer.
Oncogene. 35:1341–1352. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khan AA, Lee AJ and Roh TY: Polycomb group
protein-mediated histone modifications during cell differentiation.
Epigenomics. 7:75–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bejarano F, González I, Vidal M and
Busturia A: The drosophila RYBP gene functions as a
polycomb-dependent transcriptional repressor. Mech Dev.
122:1118–1129. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pirity MK, Locker J and Schreiber-Agus N:
Rybp/DEDAF is required for early postimplantation and for central
nervous system development. Mol Cell Biol. 25:7193–7202. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Endam LM, Filali-Mouhim A, Zhao
L, Desrosiers M, Han D and Zhang L: Polymorphisms in RYBP and AOAH
genes are associated with chronic rhinosinusitis in a Chinese
population: A replication study. PLoS One. 7:e392472012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Novak RL and Phillips AC:
Adenoviral-mediated RYBP expression promotes tumor cell-specific
apoptosis. Cancer Gene Ther. 15:713–722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen D, Zhang J, Li M, Rayburn ER, Wang H
and Zhang R: RYBP stabilizes p53 by modulating MDM2. EMBO Rep.
10:166–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scott GK, Mattie MD, Berger CE, Benz SC
and Benz CC: Rapid alteration of microRNA levels by histone
deacetylase inhibition. Cancer Res. 66:1277–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lando M, Wilting SM, Snipstad K, Clancy T,
Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, et
al: Identification of eight candidate target genes of the recurrent
3p12-p14 loss in cervical cancer by integrative genomic profiling.
J Pathol. 230:59–69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lando M, Holden M, Bergersen LC, Svendsrud
DH, Stokke T, Sundfør K, Glad IK, Kristensen GB and Lyng H: Gene
dosage, expression, and ontology analysis identifies driver genes
in the carcinogenesis and chemoradioresistance of cervical cancer.
PLoS Genet. 5:e10007192009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krohn A, Seidel A, Burkhardt L, Bachmann
F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, et
al: Recurrent deletion of 3p13 targets multiple tumour suppressor
genes and defines a distinct subgroup of aggressive ERG
fusion-positive prostate cancers. J Pathol. 231:130–141. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feik E, Schweifer N, Baierl A,
Sommergruber W, Haslinger C, Hofer P, Maj-Hes A, Madersbacher S and
Gsur A: Integrative analysis of prostate cancer aggressiveness.
Prostate. 73:1413–1426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lindsey S and Langhans SA: Crosstalk of
oncogenic signaling pathways during epithelial-mesenchymal
transition. Front Oncol. 4:3582014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mitra A, Mishra L and Li S: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gregory PA, Bracken CP, Smith E, Bert AG,
Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, et al:
An autocrine TGF-beta/ZEB/miR-200 signaling network regulates
establishment and maintenance of epithelial-mesenchymal transition.
Mol Biol Cell. 22:1686–1698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Z, Sun B, Qi L, Li H, Gao J and Leng
X: Zinc finger E-box binding homeobox 1 promotes vasculogenic
mimicry in colorectal cancer through induction of
epithelial-to-mesenchymal transition. Cancer Sci. 103:813–820.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kurahara H, Takao S, Maemura K, Mataki Y,
Kuwahata T, Maeda K, Ding Q, Sakoda M, Iino S, Ishigami S, et al:
Epithelial-mesenchymal transition and mesenchymal-epithelial
transition via regulation of ZEB-1 and ZEB-2 expression in
pancreatic cancer. J Surg Oncol. 105:655–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fritz A April, Percy C, Jack A,
Shanmugaratnam K, Sobin L, Parkin DM and Whelan S: World Health
Organization: International Classification of Diseases for
Oncology. 3rd. WHO Press; Geneva: 2000
|
|
27
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: A study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sánchez-Tilló E, Lázaro A, Torrent R,
Cuatrecasas M, Vaquero EC, Castells A, Engel P and Postigo A: ZEB1
represses E-cadherin and induces an EMT by recruiting the SWI/SNF
chromatin-remodeling protein BRG1. Oncogene. 29:3490–3500. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cong N, Du P, Zhang A, Shen F, Su J, Pu P,
Wang T, Zjang J, Kang C and Zhang Q: Downregulated microRNA-200a
promotes EMT and tumor growth through the wnt/β-catenin pathway by
targeting the E-cadherin repressors ZEB1/ZEB2 in gastric
adenocarcinoma. Oncol Rep. 29:1579–1587. 2013.PubMed/NCBI
|
|
30
|
Vandewalle C, Comijn J, De Craene B,
Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F and
Berx G: SIP1/ZEB2 induces EMT by repressing genes of different
epithelial cell-cell junctions. Nucleic Acids Res. 33:6566–6578.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Garcia E, Marcos-Gutiérrez C, del Mar
Lorente M, Moreno JC and Vidal M: RYBP, a new repressor protein
that interacts with components of the mammalian polycomb complex,
and with the transcription factor YY1. EMBO J. 18:3404–3418. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sánchez-Beato M, Sánchez E, Garcia JF,
Pérez-Rosado A, Montoya MC, Fraga M, Artiga MJ, Navarrete M,
Abraira V, Morente M, et al: Abnormal PcG protein expression in
hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription
factors. J Pathol. 204:528–537. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sánchez-Beato M, Sánchez E,
González-Carreró J, Morente M, Diez A, Sánchez-Verde L, Martin MC,
Cigudosa JC, Vidal M and Piris MA: Variability in the expression of
polycomb proteins in different normal and tumoral tissues. A pilot
study using tissue microarrays. Mod Pathol. 19:684–694. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang W, Cheng J, Qin JJ, Voruganti S, Nag
S, Fan J, Gao Q and Zhang R: RYBP expression is associated with
better survival of patients with hepatocellular carcinoma (HCC) and
responsiveness to chemotherapy of HCC cells in vitro and in vivo.
Oncotarget. 5:11604–11619. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu JM, Sun W, Hua F, Xie J, Lin H, Zhou DD
and Hu ZW: BCL6 induces EMT by promoting the ZEB1-mediated
transcription repression of E-cadherin in breast cancer cells.
Cancer Lett. 365:190–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Galván JA, Zlobec I, Wartenberg M, Lugli
A, Gloor B, Perren A and Karamitopoulou E: Expression of E-cadherin
repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells
influences tumour-budding phenotype and suggests heterogeneity of
stromal cells in pancreatic cancer. Br J Cancer. 112:1944–1950.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cai MY, Luo RZ, Chen JW, Pei XQ, Lu JB,
Hou JH and Yun JP: Overexpression of ZEB2 in peritumoral liver
tissue correlates with favorable survival after curative resection
of hepatocellular carcinoma. PLoS One. 7:e328382012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Siles L, Sánchez-Tilló E, Lim JW, Darling
DS, Kroll KL and Postigo A: ZEB1 imposes a temporary
stage-dependent inhibition of muscle gene expression and
differentiation via CtBP-mediated transcriptional repression. Mol
Cell Biol. 33:1368–1382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang J, Lee S, Teh CE, Bunting K, Ma L and
Shannon MF: The transcription repressor, ZEB1, cooperates with
CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. Int
Immunol. 21:227–235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Elsum IA, Martin C and Humbert PO:
Scribble regulates an EMT polarity pathway through modulation of
MAPK-ERK signaling to mediate junction formation. J Cell Sci.
126:3990–3999. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu Y, El-Naggar S, Darling DS, Higashi Y
and Dean DC: Zeb1 links epithelial-mesenchymal transition and
cellular senescence. Development. 135:579–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang J, Lu C, Zhang J, Kang J, Cao C and
Li M: Involvement of ZEB1 and E-cadherin in the invasion of lung
squamous cell carcinoma. Mol Biol Rep. 40:949–956. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ran J, Lin DL, Wu RF, Chen QH, Huang HP,
Qiu NX and Quan S: ZEB1 promotes epithelial-mesenchymal transition
in cervical cancer metastasis. Fertil Steril. 103:1606–1614.e1-e2.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Koopmansch B, Berx G, Foidart JM, Gilles C
and Winkler R: Interplay between KLF4 and ZEB2/SIP1 in the
regulation of E-cadherin expression. Biochem Biophys Res Commun.
431:652–657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dai YH, Tang YP, Zhu HY, Lv L, Chu Y, Zhou
YQ and Huo JR: ZEB2 promotes the metastasis of gastric cancer and
modulates epithelial mesenchymal transition of gastric cancer
cells. Dig Dis Sci. 57:1253–1260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Si W, Huang W, Zheng Y, Yang Y, Liu X,
Shan L, Zhou X, Wang Y, Su D, Gao J, et al: Dysfunction of the
reciprocal feedback loop between GATA3- and ZEB2-nucleated
repression programs contributes to breast cancer metastasis. Cancer
Cell. 27:822–836. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang Z, Sun B, Li Y, Zhao X, Zhao X, Gu Q,
An J, Dong X, Liu F and Wang Y: ZEB2 promotes vasculogenic mimicry
by TGF-β1 induced epithelial-to-mesenchymal transition in
hepatocellular carcinoma. Exp Mol Pathol. 98:352–359. 2015.
View Article : Google Scholar : PubMed/NCBI
|
